No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

No­var­tis is buy­ing gene ther­a­py and neu­ro­science biotech Kate Ther­a­peu­tics in a deal worth $1.1 bil­lion in up­front and mile­stone pay­ments, the Swiss phar­ma con­firmed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER